From the F.I. Proctor Foundation (I.A., S.J.S., D.C.M., Y.S., B.F.A., J.D.K., N.R.A.).
From the F.I. Proctor Foundation (I.A., S.J.S., D.C.M., Y.S., B.F.A., J.D.K., N.R.A.); Department of Ophthalmology (B.F.A., N.R.A.).
Am J Ophthalmol. 2024 Feb;258:139-144. doi: 10.1016/j.ajo.2023.07.004. Epub 2023 Jul 7.
Herpes zoster ophthalmicus (HZO) after COVID-19 vaccination has been reported in numerous case studies. However, no large-scale epidemiologic studies have been conducted to date. The purpose of this study was to determine whether COVID-19 vaccination is associated with an increased risk of HZO.
Retrospective before-and-after risk interval analysis.
RESULTS: In total, 1,959,157 patients received a dose of a COVID-19 vaccine during the study period and met eligibility criteria. A total of 80 individuals without a prior history of HZO were included in the analysis because they developed HZO in the risk or control period. Patients had a mean age of 54.0 years (SD = 12.3 years). There were 45 cases of HZO in the risk interval after COVID-19 vaccination. There was not an increased risk of HZO after vaccination with BNT162b2 (IRR = 0.90, 95% CI: 0.49-1.69, P = .74), mRNA-1273 (IRR = 0.74, 95% CI: 0.36-1.54, P = .42), or Ad26.COV2.S (IRR = 0.50, 95% CI: 0.07-2.56, P = .42).
This study found no evidence of increased risk of HZO after COVID-19 vaccination, providing reassurance for patients and providers who may be concerned about the safety profile of the COVID-19 vaccines.
带状疱疹（HZO）在 COVID-19 疫苗接种后已在许多病例研究中报道。然而，迄今为止，尚未进行大规模的流行病学研究。本研究旨在确定 COVID-19 疫苗接种是否与 HZO 风险增加相关。
回顾性前后风险间隔分析。
在研究期间，共有 1959157 名患者接种了一剂 COVID-19 疫苗，符合入选标准。共有 80 名没有 HZO 既往史的患者被纳入分析，因为他们在风险或对照期发生了 HZO。患者的平均年龄为 54.0 岁（SD=12.3 岁）。在 COVID-19 疫苗接种后的风险间隔内发生了 45 例 HZO。接种 BNT162b2（IRR=0.90，95%CI：0.49-1.69，P=0.74）、mRNA-1273（IRR=0.74，95%CI：0.36-1.54，P=0.42）或 Ad26.COV2.S（IRR=0.50，95%CI：0.07-2.56，P=0.42）后，HZO 的风险没有增加。
本研究未发现 COVID-19 疫苗接种后 HZO 风险增加的证据，为可能担心 COVID-19 疫苗安全性的患者和提供者提供了保证。
